ACOR Acorda Therapeutics Inc.

+0.05  (+0%)
Previous Close 18.15
Open 18.15
Price To Book 1.42
Market Cap 864205397
Shares 47,483,813
Volume 3,782,664
Short Ratio 11.57
Av. Daily Volume 616,741

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
Improve walking in patients with multiple sclerosis
Phase 1 complete. Noted November 2017 that it will not advance into a Phase 2 study by the end of 2017, as previously expected. Evaluating next steps.
Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Company noted November 20, 2017 that program will be discontinued.
Parkinson’s disease (PD)
Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
Post stroke deficits
Refuse-To-File letter August 30, 2017. New PDUFA date October 5, 2018 extended to January 5, 2018.
OFF episodes of Parkinson’s disease (PD)
Phase 2 data due 2Q 2018 (overdue - shifted to 3Q in calendar).
Primary Sclerosing Cholangitis

Latest News

  1. See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
  2. Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija
  3. Qualcomm and Tailored Brands rise; Kroger stumbles
  4. Here's Why Acorda Therapeutics Is Falling by Double Digits Today
  5. Acorda shares slide 19% premarket after FDA delays review of Parkinson's treatment
  6. Acorda Announces FDA Extends INBRIJA NDA Review Period
  7. Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down
  8. Are Options Traders Betting on a Big Move in Acorda (ACOR) Stock?
  9. Today’s Research Reports on Stocks to Watch: Acorda Therapeutics and Avid Bioservices
  10. Why Brown-Forman, Acorda Therapeutics, and Energy XXI Gulf Coast Slumped Today
  11. What's Behind Acorda Therapeutics Crashing 24.5% Today
  12. Acorda's stock plunges after disappointing ruling regarding patents for MS treatment
  13. U.S. Court of Appeals for the Federal Circuit Upholds District Court’s Decision to Invalidate AMPYRA® (dalfampridine) Patents
  14. Market Trends Toward New Normal in Acorda Therapeutics, Red Robin Gourmet Burgers, Plug Power, Group 1 Automotive, Shutterfly, and National Fuel Gas — Emerging Consolidated Expectations, Analyst Ratings
  15. Acorda Announces Management Transitions
  16. Edited Transcript of ACOR earnings conference call or presentation 2-Aug-18 12:30pm GMT
  17. Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates